Pulmonx Corporation (LUNG) Tops Q2 EPS by 1c

Pulmonx Corporation (NASDAQ: LUNG) reported Q2 EPS of ($0.40), $0.01 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $14 million versus the consensus estimate of $13.77 million.

GUIDANCE:

Pulmonx Corporation sees FY2022 revenue of $55-60 million, versus the consensus of $58.5 million.

For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Farmmi announces public offering of Class A ordinary shares
• SYNNEX Corp. (SNX) Tops Q2 EPS by 74c, Beats on Revenue; Offers Q3 Guidance